Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 9,958 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
9,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
142
States / cities
Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 2:08 AM EDT
Recruiting Phase 3 Interventional

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

NCT07382167
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
109
States / cities
Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

NCT00257192
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment Outcomes of ReACT for PNES

NCT02801136
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT, Supportive Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability and Functional Assessment of a Novel Children's Synbiotic

NCT04534036
View directory record Official record
Conditions
Constipation, Signs and Symptoms, Digestive Signs and Symptoms, Infrequent or Difficult Evacuation
Interventions
PDS-08, Placebo
Dietary Supplement · Other
Lead sponsor
Seed Health
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

NCT02706834
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-828, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses

NCT02423109
View directory record Official record
Conditions
Myopia, Hyperopia, Astigmatism
Interventions
fanfilcon A, enfilcon A
Device
Lead sponsor
CooperVision, Inc.
Industry
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
macitentan (ACT-064992), placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 21, 2026, 2:08 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.

NCT01377441
View directory record Official record
Conditions
Inflammatory Response
Interventions
Ibuprofen, Placebo/Saline solution
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 21, 2026, 2:08 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

NCT02436031
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Desipramine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 2:08 AM EDT
Not listed Phase 2 Interventional

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

NCT01408602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MRC375, Matching Placebo, MRC375 150mg
Drug
Lead sponsor
Molecular Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
19
States / cities
Mobile, Alabama • Long Beach, California • Los Alamitos, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

NCT04098302
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Dutasteride Capsules, Placebo Capsules
Drug
Lead sponsor
UConn Health
Other
Eligibility
35 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

NCT04303195
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
NG101, Placebo
Drug
Lead sponsor
Neurogastrx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
83
States / cities
Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Improving Insulin Therapy With Enhanced Care Management

NCT00320112
View directory record Official record
Conditions
Diabetes
Interventions
Reciprocal Diabetes Peer Support Program, Nurse Case management, group outpatient counseling visits
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 21, 2026, 2:08 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Not applicable Interventional

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270
View directory record Official record
Conditions
Gram-Positive Bacterial Infections, Vancomycin, Pharmacokinetics, Pharmacodynamics
Interventions
Computer Decision Support Tool Intervention Group, Matched Historical Controls
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 2:08 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

NCT03685773
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders
Interventions
Diazoxide, Placebo (for diazoxide), Nicotinic acid
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 21, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 2:08 AM EDT